Published: Mar-2021 | Format: PDF | Market Research Store | Number of pages: 120 | Code: MRS - 828542
The acute lymphoblastic leukemia market is set for rapid growth over the forecast period. In terms of revenue, the global acute lymphoblastic leukemia market accounted for USD 2,500 Million in 2019 and is expected to reach USD 3,500 Million by 2026, growing at a CAGR of 5.4%.
Acute lymphoblastic leukemia (ALL) is a type of bone marrow and blood cancer. It is more common in children and if treated there is a good chance for curing it. It can also be found in adults however the chances of cure reduce in the case of adults. The ALL starts from the bone marrow where new blood cells are made. The leukemia cells can sometimes also spread to different parts of the body such as the spleen, testicles, liver, lymph nodes, and central nervous system.
The global acute lymphoblastic leukemia market is driven by technological advancements in the detection of affected cells. The growth of the market can also be attributed to the growing number of cases of bone marrow biopsies. The increasing number of cancer cases globally among the geriatric population is also anticipated to boost the market. Some of the drugs that are used in acute lymphoblastic leukemia are Cyclophosphamide by Baxter, Amsacrine by NordMedica, and Cytarabine by Pfizer. The development of new therapies is giving the market significant momentum. For instance, Novartis AG developed a novel cell therapy for Chimeric Antigen Receptor (CAR)-T cells. The novel therapy is anticipated to receive approval from FDA by 2020 and is currently in phase II clinical trials. Various initiatives are taken by the government and different organizations such as National Cancer Institute, American Cancer Society, and FNIH to fight against acute lymphoblastic leukemia. Based on data published in 2017 by the American Cancer Society, there were around 3,350 males and 2,620 females diagnosed with acute lymphoblastic leukemia among which 800 males and 640 females were estimated to die from the condition.
The global acute lymphoblastic leukemia market is segmented into its type, therapy type, drug, and regions. On the basis of the type, the global market is segregated into adults and pediatrics. Based on the therapy type, the market is bifurcated into targeted therapy, stem cell transplantation, chemotherapy, and radiation therapy. On the basis of drugs, the global market is segmented into linker regimen, targeted drugs & immunotherapy, oncaspar, hyper-CVAD regimen, nucleoside metabolic inhibitors, CALGB 8811 regimen, and others. Geographically, the global acute lymphoblastic leukemia market is diversified into North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa.
North America region dominated the global acute lymphoblastic leukemia market in 2019 and is anticipated to continue its dominance in the upcoming years. The dominance of the North America market can be attributed to the presence of key players in the region, easy accessibility of diagnosis, and high treatment cost. The Asia Pacific region is anticipated to grow at the highest rate in the forecast period owing to the rising population in the region and increasing awareness of the population towards cancer treatment.
Some of the key players in the acute lymphoblastic leukemia market are Celegene Corporation, Erytech Pharma, Genmab A/S, Novartis AG, Sanofi SA, Bristol Myer Squibb Company, Eisai Co Ltd, Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, and Pfizer Inc. among others.
Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia